Published in J Virol on September 01, 2002
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology (2006) 1.66
Nonsegmented negative-strand viruses as vaccine vectors. J Virol (2006) 1.53
Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol (2004) 1.46
A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol (2005) 1.45
Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol (2006) 1.42
Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA. J Virol (2006) 1.34
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis (2012) 1.32
Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J Virol (2004) 1.28
Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology (2007) 1.22
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther (2009) 1.22
Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol (2006) 1.12
Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol (2007) 0.97
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine (2008) 0.97
Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. J Virol (2011) 0.96
Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol (2006) 0.93
Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics (2008) 0.92
Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein. J Virol (2004) 0.90
The current status and future directions of myxoma virus, a master in immune evasion. Vet Res (2011) 0.90
CD4+ T-cell reconstitution reduces cytomegalovirus in the immunocompromised brain. J Virol (2005) 0.88
Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates. J Virol (2014) 0.88
Vesicular stomatitis virus genomic RNA persists in vivo in the absence of viral replication. J Virol (2009) 0.87
Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs. PLoS One (2012) 0.86
Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease. Virol J (2013) 0.86
Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein. Clin Vaccine Immunol (2008) 0.85
Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. Virology (2015) 0.83
New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention. Antivir Ther (2011) 0.79
Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas. Virol J (2008) 0.79
Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potency. J Virol (2009) 0.79
Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity. Comp Med (2008) 0.78
A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice. PLoS One (2014) 0.77
Construction of a Sonchus Yellow Net Virus minireplicon: a step toward reverse genetic analysis of plant negative-strand RNA viruses. J Virol (2013) 0.77
Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine (2016) 0.76
Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection. Hum Vaccin Immunother (2016) 0.75
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A (1986) 32.58
INFECTIOUS PAPILLOMATOSIS OF RABBITS : WITH A NOTE ON THE HISTOPATHOLOGY. J Exp Med (1933) 15.65
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J Virol (1982) 5.49
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 4.79
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol (1998) 3.07
Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol (1999) 3.04
Human papillomaviruses. Annu Rev Microbiol (1994) 2.88
Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology (1992) 2.53
Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol (1994) 2.52
The pathogenesis of the rabbit papilloma-to-carcinoma sequence. Ann N Y Acad Sci (1952) 2.36
Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J Virol (1999) 2.35
High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol (1997) 2.07
Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol (2001) 2.02
Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol (1996) 1.66
Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine (1995) 1.53
Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway. J Virol (1999) 1.43
Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product. J Virol (1993) 1.23
Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis (1996) 1.19
A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology (1994) 1.15
Towards vaccines against human papillomavirus type-16 genital infections. Vaccine (1993) 1.02
Animal models of human-papillomavirus-associated oncogenesis. Intervirology (1994) 1.02
Human papillomavirus and human disease. Am J Med (1997) 0.99
Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today (1999) 0.99
Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge . Vaccine (1997) 0.96
Immune response to genital papillomavirus infections in women. Prospects for the development of a vaccine against cervical cancer. Ann N Y Acad Sci (1993) 0.94
Skin test to assess immunity against cottontail rabbit papillomavirus antigens in rabbits with progressing papillomas or after papilloma regression. J Invest Dermatol (1993) 0.90
Optimization of cottontail rabbit papilloma virus challenge technique. J Virol Methods (2001) 0.89
Shope rabbit papilloma--carcinoma complex. A model system of HPV infections. Clin Dermatol (1989) 0.82
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A (2004) 3.40
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
A single-center strategy to minimize blood transfusion in neonates and children undergoing cardiac surgery. Paediatr Anaesth (2015) 2.01
Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology (2004) 1.91
Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS. Proc Natl Acad Sci U S A (2009) 1.78
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology (2005) 1.74
Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys (2010) 1.72
Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol (2002) 1.69
Association between single nucleotide polymorphisms of the transforming growth factor β1 gene and the risk of severe radiation esophagitis in patients with lung cancer. Radiother Oncol (2012) 1.62
Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol (2002) 1.61
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
Local type I IFN receptor signaling protects against virus spread within the central nervous system. J Immunol (2009) 1.57
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol (2005) 1.54
A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol (2006) 1.51
Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol (2002) 1.49
Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer (2008) 1.49
Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol (2004) 1.46
Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses (2004) 1.45
A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol (2005) 1.45
Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses (2005) 1.45
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis (2005) 1.44
Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys (2012) 1.43
High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J Virol (2002) 1.37
Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys (2011) 1.37
Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA. J Virol (2006) 1.34
A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J Virol (2010) 1.33
SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog (2010) 1.32
Is there an ideal animal model for SARS? Trends Microbiol (2006) 1.28
Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J Virol (2004) 1.28
Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol (2014) 1.26
Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J Virol (2009) 1.25
Clinical gaseous microemboli assessment of an oxygenator with integral arterial filter in the pediatric population. J Extra Corpor Technol (2009) 1.23
Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology (2007) 1.22
Calcium phosphate transfection. Curr Protoc Mol Biol (2003) 1.22
Contributions from radiation damping and surface scattering to the linewidth of the longitudinal plasmon band of gold nanorods: a single particle study. Phys Chem Chem Phys (2006) 1.20
In-vitro quantification of gaseous microemboli in two extracorporeal life support circuits. J Extra Corpor Technol (2011) 1.19
The viral E4 protein is required for the completion of the cottontail rabbit papillomavirus productive cycle in vivo. J Virol (2004) 1.18
A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol (2005) 1.17
Interaction of glycoprotein H of human herpesvirus 6 with the cellular receptor CD46. J Biol Chem (2003) 1.16
Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases. Hum Pathol (2010) 1.14
Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J Virol (2010) 1.14
Functional polymorphisms of base excision repair genes XRCC1 and APEX1 predict risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.12
Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys (2011) 1.11
Development of the international thymic malignancy interest group international database: an unprecedented resource for the study of a rare group of tumors. J Thorac Oncol (2014) 1.10
Viral strategies for studying the brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi-like expression. J Comp Neurol (2009) 1.09
Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. Cancer (2011) 1.08
Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease. J Virol (2011) 1.07
Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol (2013) 1.06
Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy. PLoS One (2011) 1.06
A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol (2008) 1.05
Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J Virol (2011) 1.05
Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol (2011) 1.05
Endoscopic biopsies of duodenal polyp/mass lesions: a surgical pathology review. J Clin Pathol (2010) 1.04
Requirement for CD4 T cell help in maintenance of memory CD8 T cell responses is epitope dependent. J Immunol (2007) 1.04
Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alpha. J Virol (2006) 1.04
Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys (2012) 1.03
Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer. J Nucl Med (2012) 1.02
Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology (2005) 1.02
Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis. Int J Radiat Oncol Biol Phys (2012) 1.01
SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology (2008) 1.01
Genomic analysis reveals age-dependent innate immune responses to severe acute respiratory syndrome coronavirus. J Virol (2008) 1.00
Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J Virol (2002) 0.99
Generation of dendritic cells from rabbit bone marrow mononuclear cell cultures supplemented with hGM-CSF and hIL-4. Vet Immunol Immunopathol (2005) 0.98
Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine (2011) 0.98
Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J Gen Virol (2003) 0.98
Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol (2007) 0.97
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine (2008) 0.97
Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine (2006) 0.97
Functional promoter rs2868371 variant of HSPB1 associates with radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with radio(chemo)therapy. Radiother Oncol (2011) 0.96
Characterization of behavioral and neuromuscular junction phenotypes in a novel allelic series of SMA mouse models. Hum Mol Genet (2012) 0.96
Perfusion techniques toward bloodless pediatric open heart surgery. J Extra Corpor Technol (2010) 0.96
Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma. J Thorac Oncol (2011) 0.95
A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. J Virol (2012) 0.95
TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer (2011) 0.94
ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys (2012) 0.93
Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys (2013) 0.92
Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine (2009) 0.92
Therapeutic efficacy of vesicular stomatitis virus-based E6 vaccination in rabbits. Vaccine (2006) 0.91
Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach. J Virol (2010) 0.91
Systemic immune deficiency necessary for cytomegalovirus invasion of the mature brain. J Virol (2004) 0.91
Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein. J Virol (2004) 0.90
Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV). Vaccine (2006) 0.90
CD4+ T-cell reconstitution reduces cytomegalovirus in the immunocompromised brain. J Virol (2005) 0.88
A new method to position and functionalize metal-organic framework crystals. Nat Commun (2011) 0.88
Identification of a region in the stalk domain of the nipah virus receptor binding protein that is critical for fusion activation. J Virol (2013) 0.88
An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine (2006) 0.88
Vesicular stomatitis virus genomic RNA persists in vivo in the absence of viral replication. J Virol (2009) 0.87
Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. J Virol (2003) 0.87
Validation of an enzyme-linked immunosorbent assay for detection of mouse parvovirus infection in laboratory mice. Comp Med (2002) 0.87